Self-Assembled Nanoparticles with Kynureninase-Fc Fusion Protein and Pheophorbide A for Photodynamic Immunometabolic Cancer Therapy
Source abstract
Abstract
Background/Objectives: Aberrant metabolism in tumors exacerbates the immunosuppressive tumor microenvironment. The immunosuppressive metabolite kynurenine inhibits the activation of effector T cells. Current antitumor drugs targeting kynurenine focus on small molecule inhibitors, which exhibit suboptimal efficacy in suppressing kynurenine generation owing to the diversity of kynurenine synthesis pathways. In contrast, kynureninase (KYNase) can directly metabolize kynurenine regardless of the production source. However, its delivery is hindered by short blood-circulation half-life and poor tumor accumulation. Additionally, photodynamic therapy (PDT) has been reported to synergize with immunotherapy, suggesting a potential combinatorial photodynamic immunometabolic cancer therapy with KYNase. Methods: A KYNase-Fc fusion protein was prepared to prolong blood circulation and enhance tumor accumulation of KYNase. Meanwhile, KYNase-Fc served as a nanocarrier for photosensitizer pheophorbide A (PhA) due to the high binding affinity between KYNase-Fc and PhA. Through self-assembly, KYNase-Fc/PhA nanoparticles (KYNase-Fc/PhA NPs) were prepared without extra carrier materials. Results: Compared with the PEGylated KYNase, KYNase-Fc exhibited significantly prolonged blood circulation, enhanced tumor accumulation and effective tumor suppression. Moreover, the prepared KYNase-Fc/PhA NPs facilitated rapid PhA tumor accumulation. The combined photodynamic immunometabolic therapy alleviated the immunosuppressive microenvironment and significantly inhibited the growth of subcutaneous 4T1 tumors in mice. Conclusions: KYNase-Fc offered a carrier-free nanomedicine for co-delivery of PhA for photodynamic immunometabolic antitumor therapy with enhanced efficacy, providing a promising platform for clinical translation.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Photodynamic Therapy Research Studies · Nanoplatforms for cancer theranostics · Cancer Research and Treatments
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
School of Pharmaceutical Sciences, Minhang Hospital, Key Laboratory of Smart Drug Delivery Ministry of Education & State Key Laboratory of Molecular Engineering of Polymers, Fudan University, 826 Zhangheng Road, Shanghai 201203, China
Quzhou Fudan Institute, 108 Minjiang Avenue, Quzhou 324002, China
Funding
National Natural Science Foundation of China · Shanghai Municipal Health Commission · Science and Technology Commission of Shanghai Municipality
References (73)
Show source-provided references
1. The cancer immunotherapy revolution10.1126/science.359.6382.1344 ↗
2. Immune therapy for cancer10.1146/annurev.immunol.021908.132544 ↗
3. Beyond immune checkpoint blockade: Emerging immunological strategies10.1038/s41573-021-00155-y ↗
4. Immune suppressive mechanisms in the tumor microenvironment10.1016/j.coi.2015.10.009 ↗
5. Fueling the revolution: Targeting metabolism to enhance immunotherapy10.1158/2326-6066.CIR-20-0791 ↗
6. Cancer immunometabolism: Advent, challenges, and perspective10.1186/s12943-024-01981-5 ↗
7. Metabolic communication in the tumour-immune microenvironment10.1038/s41556-022-01002-x ↗
8. Cancer cell metabolism and antitumour immunity10.1038/s41577-024-01026-4 ↗
9. Oweira, H., Lahdou, I., Mehrle, S., Khajeh, E., Nikbakhsh, R., Ghamarnejad, O., Terness, P., Reissfelder, C., Sadeghi, M., and Ramouz, A. (2022). Kynurenine is the main metabolite of tryptophan degradation by tryptophan 2,3-dioxygenase in HepG2 tumor cells. J. Clin. Med., 11.10.3390/jcm11164794 ↗
10. Mor, A., Tankiewicz-Kwedlo, A., and Pawlak, D. (2021). Kynurenines as a novel target for the treatment of malignancies. Pharmaceuticals, 14.10.3390/ph14070606 ↗
11. Trial watch: IDO inhibitors in cancer therapy10.4161/21624011.2014.957994 ↗
12. First-in-human phase I study of the oral inhibitor of indoleamine 2,3-dioxygenase-1 Epacadostat (INCB024360) in patients with advanced solid malignancies10.1158/1078-0432.CCR-16-2272 ↗
13. Metabolic modulation of kynurenine based on kynureninase-loaded nanoparticle depot overcomes tumor immune evasion in cancer immunotherapy10.1021/acsami.4c00513 ↗
14. Waste disposal-an attractive strategy for cancer therapy10.1126/science.aam7340 ↗
15. Reversal of indoleamine 2,3-dioxygenase-mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme10.1038/nbt.4180 ↗
16. Enzymes as immunotherapeutics10.1021/acs.bioconjchem.7b00719 ↗
17. Therapeutic Fc-fusion proteins: Current analytical strategies10.1002/jssc.202000765 ↗
18. The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy10.1016/j.addr.2015.02.005 ↗
19. Li, Z., Xu, J., Lin, H., Yu, S., Sun, J., Zhang, C., Zhang, S., Li, T., Yang, A., and Lu, W. (2025). Interleukin-15Ralpha-sushi-Fc fusion protein co-hitchhikes interleukin-15 and pheophorbide A for cancer photoimmunotherapy. Pharmaceutics, 17.10.3390/pharmaceutics17050615 ↗
20. Second near-infrared light-activatable polymeric nanoantagonist for photothermal immunometabolic cancer therapy10.1002/adma.202101410 ↗
21. Immunometabolic rewiring in tumorigenesis and anti-tumor immunotherapy10.1186/s12943-021-01486-5 ↗
22. Recent strategies to develop innovative photosensitizers for enhanced photodynamic therapy10.1021/acs.chemrev.1c00381 ↗
23. Zinc oxide nanoparticles with catalase-like nanozyme activity and near-infrared light response: A combination of effective photodynamic therapy, autophagy, ferroptosis, and antitumor immunity10.1016/j.apsb.2024.07.002 ↗
24. Polymer-assisted PD-L1 degradation and targeted photodynamic therapy synergize to suppress immunodeficient tumors10.1016/j.apsb.2025.05.022 ↗
25. Inhibition of PDT-induced PGE2 surge for enhanced photo-immunotherapy10.1016/j.biomaterials.2025.123116 ↗
26. siRNA micelleplexes-mediated glutamine metabolism re-engineering for vascular normalization-boosted photo-immunotherapy10.1016/j.apsb.2025.02.020 ↗
27. Combined photodynamic and photothermal therapy and immunotherapy for cancer treatment: A review10.2147/IJN.S388996 ↗
28. Nanoemulsion applications in photodynamic therapy10.1016/j.jconrel.2022.09.035 ↗
29. Multifunctional nanoparticles as photosensitizer delivery carriers for enhanced photodynamic cancer therapy10.1016/j.msec.2020.111099 ↗
30. Nanotheranostics for personalized medicine10.1016/j.addr.2012.06.006 ↗
31. A tumor-pH-responsive supramolecular photosensitizer for activatable photodynamic therapy with minimal in vivo skin phototoxicity10.7150/thno.18861 ↗
32. Accumulated polymer degradation products as effector molecules in cytotoxicity of polymeric nanoparticles10.1093/toxsci/kft179 ↗
33. Rethinking cancer nanotheranostics10.1038/natrevmats.2017.24 ↗
34. Cancer nanomedicine: Progress, challenges and opportunities10.1038/nrc.2016.108 ↗
35. Kharissova, O.V., Martínez, L.M.T., and Kharisov, B.I. (2020). Nanomaterials and nanocomposites: Classification and toxicity. Handbook of Nanomaterials and Nanocomposites for Energy and Environmental Applications, Springer International Publishing.10.1007/978-3-030-11155-7 ↗
36. An “IgG-hitchhiking” approach for rapid tumor accumulation and clearance of photosensitizers10.1016/j.jconrel.2023.02.026 ↗
37. High affinity of chlorin e6 to immunoglobulin G for intraoperative fluorescence image-guided cancer photodynamic and checkpoint blockade therapy10.1021/acsnano.9b03466 ↗
38. Identification and characterization of rabbit scFv antibodies suitable for immuno-affinity separation of recombinant human kynureninase from Escherichia coli cell lysate10.1016/j.jbiosc.2023.12.016 ↗
39. PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel10.1016/j.cmpb.2010.01.007 ↗
40. Activatable polymer nanoenzymes for photodynamic immunometabolic cancer therapy10.1002/adma.202007247 ↗
41. CD133+PD-L1+ cancer cells confer resistance to adoptively transferred engineered macrophage-based therapy in melanoma10.1038/s41467-025-55876-0 ↗
42. Purification and biochemical characterization of native and pegylated form of L-asparaginase from of Aspergillus terreus and evaluation of its antiproliferative activity10.4236/aim.2012.22019 ↗
43. Delivery of therapeutic proteins10.1002/jps.22054 ↗
44. Monomeric Fc fusions: Impact on pharmacokinetic and biological activity of protein therapeutics10.2165/00063030-200620030-00002 ↗
45. In situ formed depot of elastin-like polypeptide-hirudin fusion protein for long-acting antithrombotic therapy10.1073/pnas.2314349121 ↗
46. A unique recombinant fluoroprobe targeting activated platelets allows in vivo detection of arterial thrombosis and pulmonary embolism using a novel three-dimensional fluorescence emission computed tomography (FLECT) technology10.7150/thno.18099 ↗
47. Capturing functional two-dimensional nanosheets from sandwich-structure vermiculite for cancer theranostics10.1038/s41467-021-21436-5 ↗
48. Polymersome-mediated cytosolic delivery of cyclic dinucleotide STING agonist enhances tumor immunotherapy
49. A novel cascaded energy conversion system inducing efficient and precise cancer therapy
50. Preferential tumor accumulation of polyglycerol functionalized nanodiamond conjugated with cyanine dye leading to near-infrared fluorescence in vivo tumor imaging10.1002/smll.201901930 ↗
51. Programmed sequential nanostructural conversion at nano-bio interface for synergistic cancer phototheranostics10.1038/s41401-025-01609-4 ↗
52. Analysis of PEG-lipid anchor length on lipid nanoparticle pharmacokinetics and activity in a mouse model of traumatic brain injury10.1039/D2BM01846B ↗
53. Wubuli, A., Chai, J., Liu, H., Nijat, D., Li, J., Xia, G., Cao, Q., Zhang, S., Huang, W., and Aipire, A. (2024). In vivo pharmacokinetics of Glycyrrhiza uralensis polysaccharides. Front. Pharmacol., 15.10.3389/fphar.2024.1431221 ↗
54. Potentiating cancer immunotherapies with modular albumin-hitchhiking nanobody-STING agonist conjugates10.1038/s41551-025-01400-0 ↗
55. Lymph node macrophage-targeted interferon alpha boosts anticancer immune responses by regulating CD169-positive phenotype of macrophages10.1186/s12943-025-02324-8 ↗
56. CD44-targeted vesicles encapsulating granzyme B as artificial killer cells for potent inhibition of human multiple myeloma in mice10.1016/j.jconrel.2020.02.004 ↗
57. Ponkshe, P., Wang, Y., and Tan, C. (2023). Systemic protein delivery via inhalable liposomes: Formulation and pharmacokinetics. Pharmaceutics, 15.10.3390/pharmaceutics15071951 ↗
58. Pharmacokinetics and biodistribution of human serum albumin-TIMP-2 fusion protein using near-infrared optical imaging10.18433/J3H88D ↗
59. Long-term direct visualization of passively transferred fluorophore-conjugated antibodies10.1016/j.jim.2017.07.009 ↗
60. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery10.1016/j.addr.2015.09.012 ↗
61. The entry of nanoparticles into solid tumours10.1038/s41563-019-0566-2 ↗
62. Poly(ethylene glycol) in drug delivery: Pros and cons as well as potential alternatives10.1002/anie.200902672 ↗
63. Striving for uniformity: A review on advances and challenges to achieve uniform polyethylene glycol10.1021/acs.oprd.3c00428 ↗
64. Significance of protein binding in pharmacokinetics and pharmacodynamics10.1002/jps.21916 ↗
65. Rowland, M., and Tozer, T.N. (1980). Clinical Pharmacokinetics and Pharmacodynamics: Concepts and Applications, Lippincott Williams & Wilkins.
66. Pheophorbide a-loaded casein micelle for in vivo drug delivery and efficient photodynamic therapy10.1016/j.jddst.2024.105598 ↗
67. The chlorophyll catabolite pheophorbide a as a photosensitizer for the photodynamic therapy10.2174/092986712799034879 ↗
68. State of the art in the delivery of photosensitizers for photodynamic therapy10.1016/S1011-1344(01)00267-6 ↗
69. Novel photosensitisers derived from pyropheophorbide-a: Uptake by cells and photodynamic efficiency in vitro10.1039/c0pp00038h ↗
70. Designing photosensitizers for photodynamic therapy: Strategies, challenges and promising developments10.4155/fmc.09.55 ↗
71. Structural and physico-chemical determinants of the interactions of macrocyclic photosensitizers with cells10.1007/s00249-007-0204-9 ↗
72. (2026, February 09). VISUDYNE (Verteporfin). U.S. Food and Drug Administration Website, Available online: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021119s022lbl.pdf.
73. Targeting immunogenic cancer cell death by photodynamic therapy: Past, present and future10.1136/jitc-2020-001926 ↗